9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $642000 | -$70M | 74.5% | -7860.0% | -$58M | $110M | $28M |
| 2024 | $2M | -$60M | 5.4% | -2967.6% | -$72M | $103M | $30M |
| 2023 | $1M | -$179M | 8.7% | -12448.0% | -$155M | $101M | $65M |
| 2022 | $375000 | -$166M | 94.7% | -42572.0% | -$135M | $93M | $194M |
| 2021 | — | -$107M | — | — | -$83M | — | $233M |
| 2020 | — | -$82M | — | — | -$67M | — | $213M |
| 2019 | — | -$33M | — | — | -$28M | — | $32M |
| 2018 | — | -$19M | — | — | -$14M | — | $43M |
| 2017 | — | -$5M | — | — | — | — | $887000 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $206000 | -$13M | -37.4% | -4962.6% | -$12M | $100M | $17M |
| Dec '25 | $256000 | -$13M | 87.5% | -4016.4% | -$14M | $110M | $28M |
| Sep '25 | $98000 | -$31M | 88.8% | -14518.4% | -$19M | $109M | $36M |
| Jun '25 | $120000 | -$19M | 10.8% | -13210.0% | — | $109M | $17M |
| Mar '25 | $168000 | -$7M | 91.7% | -6011.3% | -$12M | $106M | $31M |
| Dec '24 | $366000 | -$11M | -127.3% | -2866.9% | -$15M | $103M | $30M |
| Sep '24 | $214000 | -$14M | -446.7% | -7146.3% | -$16M | $104M | $40M |
| Jun '24 | $1M | -$8M | 94.4% | -1566.7% | — | $103M | $56M |
| Mar '24 | $582000 | -$27M | 86.3% | -4151.7% | — | $102M | $74M |
| Dec '23 | $376000 | -$22M | -89.9% | -5285.9% | -$27M | $101M | $65M |
| Sep '23 | $341000 | -$50M | -50.1% | -14163.3% | -$38M | $99M | $90M |
| Jun '23 | $457000 | -$54M | 94.3% | -11469.1% | — | $97M | $128M |
| Mar '23 | $206000 | -$53M | 95.6% | -24853.4% | — | $95M | $166M |
| Dec '22 | $238000 | -$55M | 96.2% | -22224.4% | -$39M | $93M | $194M |
| Sep '22 | $137000 | -$42M | 92.0% | -28459.9% | -$31M | $92M | $232M |
| Jun '22 | — | -$38M | — | — | -$33M | $61M | $233M |
| Mar '22 | — | -$31M | — | — | -$33M | — | $200M |
| Dec '21 | — | -$26M | — | — | -$20M | — | $233M |
| Sep '21 | — | -$27M | — | — | -$20M | — | $253M |
| Jun '21 | — | -$28M | — | — | -$22M | — | $273M |
How the market has priced BTAI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, BioXcel Therapeutics, Inc.'s revenue has grown 19.6% per year. These are computed facts, not advice.
As of FY2025, BioXcel Therapeutics, Inc. reported $110M of total debt against $28M of cash; operating income covered interest expense -3.0×.
In FY2025, gross margin was 74.5%, operating margin -7860.0%, and net margin -10887.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.